NCT07817316 Effects of Neurofeedback Training and tRNS on Attentional Deficits in Patients With Acquired Brain Injury
| NCT ID | NCT07817316 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospitales Nisa |
| Condition | Acquired Brain Injury Including Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-26 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-06-26 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to investigate new neuromodulation therapies for attention deficits following acquired brain injury. Brain damage can affect various domains, including motor and cognitive functions. However, cognitive deficits have many consequences on the functionality and independence of patients, and attention is an essential requirement for most of daily activities. After brain damage, cognitive rehabilitation is generally the first treatment option for attention deficits. Some studies have shown that cognitive rehabilitation is sometimes not very effective.For this reason, new therapies such as neuromodulation techniques are being investigated. Neurofeedback is a non-invasive neuromodulation therapy involving a type of computer-based training and learning, and some studies have shown that it is a promising tool to treat cognitive deficits in patients with brain injuries. Transcranial electrical stimulation (tES) is also used to modulate spontaneous brain activity. In the present study, the investigators will evaluate the effects of tES combined with neurofeedback as a therapy for attentional deficits after brain injury.
Eligibility Criteria
Inclusion Criteria: * ≥18 years old * ABI resulting from TBI, stroke, hypoxia and other etiologies * attentional deficits that are among the objectives of neurorehabilitation as established by the clinical team (scores falling in the 90% percentiles on the Conner's Continuous Performance - CCPT, on the Digit and Spatial Span Tasks and Color Trail test) * good cognitive condition (ie., scores of ≥23 in the Mini Mental State Examination * MMSE or ≥75 in the Galveston Orientation \& Amnesia Test - GOAT) Exclusion Criteria: * previous report of psychiatric and/or neurologic disorders * contraindication to computerized activities * blindness or severe visual impairments
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07817316 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Acquired Brain Injury Including Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07817316 currently recruiting?
Yes, NCT07817316 is actively recruiting participants. Contact the research team at alice.barra@irenea.es for enrollment information.
Where is the NCT07817316 trial being conducted?
This trial is being conducted at Valencia, Spain.
Who is sponsoring the NCT07817316 clinical trial?
NCT07817316 is sponsored by Hospitales Nisa. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.